As a pioneer of breakthrough medical solutions, HeartPoint Global (HPG) is paving the way for citizens worldwide to receive affordable, cutting-edge cardiac care. In response to the 92 percent of the world’s population has no access to cardiac surgery, the leading medical device company is on a mission to provide innovative, minimally invasive, and accessible cardiac care on a global scale to ensure those who would otherwise suffer from or die of cardiovascular disease receive the care they need. 

HPG’s patented Implant System (HPGS) is the first and only patented non-surgical structural heart system that addresses a variety of serious, life-threatening cardiovascular diseases. An estimated 17.9 million died from cardiovascular diseases in 2016, representing 31 percent of global deaths. Of those, more than 75 percent of cardiovascular disease deaths take place in the developing world, where treatments are either not available or are far too expensive. The HPGS allows for the adjustment of blood flow and pressure during and after placement in the main pulmonary artery and/or its branches in order to restore the structure of the heart-lung system. The investigational device’s pre-clinical trials are ongoing, and clinical trials will soon begin in Europe. 

Once approved for public use, this life saving device will be distributed in both the developing and developed worlds, with an immediate focus on patients who do not have access to cardiac care. HeartPoint Global is a privately held American company with operations in the USA, Ireland, and Israel. 



Clinical Trials

Health Care

Medical Devices

HeartPoint Global Inc.

HeartPoint Global Inc.'s headquarters in Newcastle, Ireland

Description

People

Jobs